Page 60 - 2020_01-Haematologica-web

B. Dholaria et al.
Table 1. Donor-lymphocyte infusion from a haploidentical donor.
Study
T-cell depleted haplo-HCT
Lewalle et al.
(2003)65 (prospective) ALL=3
CML=1 Other=3
Dodero et al. 23 Lymphoma (2009)62 (prospective) CLL ALL MM AML
Treatments CD3+ before DLI dose/kg
None 1-4x104
None 2-15x104
N. of patients Diagnosis (prospective/
retrospective)
Indication for DLI
Prophylactic=12
Prophylactic-23
N. of DLI (median)
2
1
1
1-7 (1)
1-3 (1)
1
1-4(1)
1
NA
NA
NA
Disease response
NA
NA
NA
CR=18%
CR=75%
NA
NA
NA
CR=64%
Rate of GvHD
58%
aGvHD=26% (grade 3-4=9%) cGvHD=15% (extensive=12%)
aGvHD (grade ≥2)=15% cGvHD=16% (extensive=7%)
aGvHD (grade 3-4)=4% cGvHD=16% (extensive=7%)
46%
aGvHD=55% (grade 3-4=30%) cGvHD=64% (extensive=30%)
aGvHD=31% (grade 3-4=8%) cGvHD=43% (extensive=34%)
aGvHD=53% (grade 3-4=28%)
aGvHD=48% (grade 3-4=10%) cGvHD=39% (extensive=31%)
aGvHD=66% (grade 3-4=40%) cGvHD=44% (extensive=42%)
Survival
1-yr RFS=50%, 1-yr OS=50%, NRM=0%
2-yr PFS=45% 2-yr OS=44% NRM=26%
CI NRM=40% 46-m relapse =5%
2-yr OS=63% 2-yr NRM=25%
NRM=11%
2-yr DFS=40% NRM=25%
3-yr DFS=56% 3-yr OS=58% 3-yr NRM=14%
2-yr CIR=35% 2-yr OS=47% 2-yr NRM=34% In disease relapse, 2-yr CIR=45% 2-yr OS=19% 2-yr NRM=37%
3-yr DFS=22% 3-yr OS=31% 2-yr NRM=38%
1-yr DFS=36% 1-yr OS=36% 1-yr NRM=14%
3-yr DFS=24% 3-yr OS=25% 3-yr NRM=13%
AML/MDS, 3-yr DFS=57% 3-yr NRM=7% ALL, 3-yr DFS=49% 3-yr NRM=11%
Notes
T-/B-cell depleted graft
CD8+ T-cell depleted DLI
12 AML=5
Martelli et al. 43 AML=33
61 6
(2014) (prospective) ALL=10
Gilman et al. 34 AML/MDS=13 Prophylactic-34 (2018)60 (prospective) ALL=10
Treg onday0 con
T-cell replete haplo-HCT
Or et al. (2006)106
Huang et al. (2007)38*
Yan et al. (2012)31*
Yan et al. (2012)69*
Wang et al. (2012)66*
Yan et al. (2013)33*
Yan et al. (2015)39*
Mo et al. (2016)36*
Other=11
28 AML=12 Prophylactic-6 (haplo-26,MMUD-2) ALL=7 Therapeutic- 22
None
None
CT=9 TKI=2
CT=32
Post-DLI-GvHD ppx=100%
Post-DLI-GvHD ppx=55%
Post-DLI-GvHD ppx=100%
Post-DLI-GvHD ppx=100%
Post-DLI-GvHD ppx=100%
Post-DLI-GvHD ppx=100%
Post-DLI-GvHD ppx=100%
Post-DLI-GvHD ppx=100%
Prophylactic-43
Treg=1.1x10 ±0.6 con
T on day-4,
3-5x104
1x102 to 15x108
0.07-4.39x108
0.75-2x108
0.13-2.11x108 CML=11 50(MRD) pts received CT.
AML=42 Prophylactic=61 CT=0% 0.9-7.2x108 ALL=19
AML=29 Therapeutic=50 CT=100% 0.11-2.07x108 ALL=21
AML=18 Therapeutic=55 CT=100% 0.19-0.74x108 ALL=23
None T =2.5x106±1.1
(retrospective)
20 (prospective)
CML=5 Other=3
AML=7 Therapeutic=20 ALL=10
CML=3
56 AML=32 Pre-emptive=56
(haplo-29, matched related-26, MUD-1) (prospective)
ALL=21 (MRD) MDS=3
CT=27 ALL=59 Therapeutic/ (MRD+)
124 AML=49 Prophylactic=74
(retrospective)
61 (retrospective)
50 (retrospective)
55 (retrospective)
101 (haplo=58) (retrospective)
MDS=5 pre-emptive= Allrelapsed
AML/MDS=69 ALL=32
Pre-emptive =101(MRD)
CT=100%
1.7-7.4x107
CR=55%
CR=76%
cGvHD=49% (extensive=42%) aGvHD=9% (grade 3-4=4%) cGvHD=59%
CR=76%
MRD negative (grade 3-4=11%)
aGvHD=44%
continued on the next page
50
haematologica | 2020; 105(1)